Securities code: 688050 securities abbreviation: Eyebright Medical Technology(Beijing) Co.Ltd(688050) Announcement No.: 2022-007 aibonod (Beijing) Medical Technology Co., Ltd
Announcement on bringing a lawsuit
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
Important content tips:
● the litigation stage of the case: the case has been filed and has not yet been heard;
● the party status of the listed company: plaintiff;
● amount involved: 21 million yuan in total;
● impact on the profits and losses of listed companies: this lawsuit will not affect the normal production and operation of the company. Since the litigation cases in this announcement have not been accepted in court, the impact of this litigation on the company’s profits in the current period or after the period is uncertain, and the final actual impact shall be subject to the judgment of the court.
1、 Basic information of this lawsuit
Aibonod (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as ” Eyebright Medical Technology(Beijing) Co.Ltd(688050) ” or “the company”) believed that Shanghai Hengtai Vision Technology Co., Ltd. (hereinafter referred to as “Hengtai vision”) infringed the company’s patent right and filed a lawsuit with the Shanghai Intellectual Property Court, Recently, I received the notice of accepting cases ([2022] Hu 73 Zhi min Chu No. 248, [2022] Hu 73 Zhi min Chu No. 249, [2022] Hu 73 Zhi min Chu No. 250) and other relevant materials issued by the court. As of the announcement date, these cases have been filed and have not yet been heard.
2、 Basic information of litigation cases
(I) litigants
Plaintiff: aibonod (Beijing) Medical Technology Co., Ltd
Defendant: Shanghai Hengtai Visual Technology Co., Ltd
(II) facts and reasons
Eyebright Medical Technology(Beijing) Co.Ltd(688050) take R & D and innovation as the gene and foothold, and its main business is ophthalmic medical devices, including self-developed core products such as corneal shaping lenses. The company is the legal patentee of patents zl201721682214.7, zl201410039031.8 and zl201420052215.3. Hengtai vision has been promising to sell, sell and import the product “MaiErKang myok” suspected of infringing the company’s patent involved, which infringed on the legitimate rights and interests of Eyebright Medical Technology(Beijing) Co.Ltd(688050) and caused economic losses to the company.
1. Patent involved: No. zl201721682214.7, named “corneal shaping lens”;
Amount involved: 7 million yuan;
Claim:
(1) Order Hengtai vision to immediately stop selling, promising to sell and importing products that infringe the plaintiff’s No. zl201721682214.7;
(2) Order the defendant to destroy all the infringing products in stock immediately;
(3) The defendant was ordered to compensate the plaintiff for economic losses and reasonable expenses incurred to stop the infringement, totaling 7 million yuan.
2. Patent involved: No. zl201410039031.8, named “corneal shaping lens”;
Amount involved: 7 million yuan;
Claim:
(1) Order Hengtai vision to immediately stop selling, promising to sell and importing products infringing the plaintiff’s No. zl201410039031.8;
(2) Order the defendant to destroy all the infringing products in stock immediately;
(3) The defendant was ordered to compensate the plaintiff for economic losses and reasonable expenses incurred to stop the infringement, totaling 7 million yuan.
3. Patent involved: No. zl201420052215.3, named “corneal shaping lens”;
Amount involved: 7 million yuan;
Claim:
(1) Order Hengtai vision to immediately stop selling, promising to sell and importing products infringing the plaintiff’s No. zl201420052215.3;
(2) Order the defendant to destroy all the infringing products in stock immediately;
(3) The defendant was ordered to compensate the plaintiff for economic losses and reasonable expenses incurred to stop the infringement, totaling 7 million yuan.
3、 Impact of this lawsuit on the company
The company is the plaintiff in this lawsuit, and this lawsuit will not affect the normal production and operation of the company. Since the litigation cases in this announcement have not been accepted in court, the impact of this litigation on the company’s profits in the current period or after the period is uncertain, and the final actual impact shall be subject to the judgment of the court.
Eyebright Medical Technology(Beijing) Co.Ltd(688050) adhere to independent innovation. This lawsuit advocates its own legitimate rights and interests according to law and earnestly protects the interests of the company and shareholders. The board of directors of the company attaches great importance to and will pay close attention to the progress of this matter. In view of the total amount involved in this lawsuit is 21 million yuan, which has reached the disclosure standard specified in the Listing Rules of science and Innovation Board of Shanghai Stock Exchange, the company will disclose the progress of the lawsuit in strict accordance with the requirements of relevant laws, regulations and normative documents, and fulfill the obligation of information disclosure in time. Please pay attention to investment risks.
It is hereby announced.
Board of directors of aibonod (Beijing) Medical Technology Co., Ltd. February 16, 2022
